Phase 1 Dermal Safety Study of XF-73
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Exeporfinium chloride (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions
- 23 Sep 2019 Status changed from recruiting to completed, according to a Destiny pharma media release.
- 28 Jan 2019 Results published in a Destiny pharma media release.
- 13 Apr 2018 New trial record